A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Inclusion Criteria

• •Adult participants of all genders (≥18 years old)
• •Diagnosis of CKD associated with T2D based on assessment by physician.
• •Treatment according to local marketing authorization, finerenone 20 or 10 mg.Treatment should have been started up to 8 weeks before or after the ICF is signed.
• •Decision to initiate treatment with finerenone must be made before ICF is signed.
• •Signed informed consent